After the review of the data and barring any further inquiries or requests,
the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US. After such designation, the Company will pursue other clinical applications of Escozine®, including as potential cancer therapeutic where the Company has already released positive clinical results.
QNTA is the cheapest COVID-19 and cancer treatment play for small cap investors to watch.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.